NCT04825938View on ClinicalTrials.gov

Neoadjuvant Toripalimab in Combination With Carboplatin and Nab-paclitaxel in Untreated Salivary Gland Malignant Neoplasms

PHASE2Not yet recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

April 30, 2021

Primary Completion Date

June 1, 2022

Study Completion Date

June 1, 2027

Conditions

Salivary Gland Malignant NeoplasmsSalivary Gland Tumors

Interventions

DRUG

Toripalimab , Carboplatin, Nab-paclitaxel

Patients receive toripalimab IV on day 1, paclitaxel IV on day 1 and carboplatin IV on day 1 . Treatment repeats every 21 days for up to 2 courses in the absence of disease progression or unacceptable toxicity.

Trial Locations (1)

510000

Sun Yat-sen Memorial Hospital, Guangzhou

All Listed Sponsors

lead

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

OTHER